IJC:他汀改善冠脉微血管功能障碍

2011-12-12 MedSci原创 MedSci原创

12月7日,在线发表于《国际心脏病学杂志》(Int J Cardiol)的一项研究论文"Beneficial effects of statin treatment on coronary microvascular dysfunction and left ventricular remodeling in patients with acute myocardial infarction"表明

12月7日,在线发表于《国际心脏病学杂志》(Int J Cardiol)的一项研究论文"Beneficial effects of statin treatment on coronary microvascular dysfunction and left ventricular remodeling in patients with acute myocardial infarction"表明,他汀除降脂作用外,还能够改善冠脉内皮细胞功能。

近日,日本学者研究表明,他汀治疗似对于急性心肌梗死(AMI)后左室重构的改善有益,其作用可能与通过内源性一氧化氮恢复冠脉内皮功能有关。研究者将35例AMI后行成功的再灌注治疗的患者分为他汀治疗组(S组)和非他汀治疗组(NS组)。采用13N-氨正电子发射断层摄影术评价梗死区域的心肌血流储备(MFR)。

结果显示,在长期治疗中,两组的梗死面积和血脂谱相似。在AMI发生2周后,S组梗死区的平均MFR显著高于NS组[(2.34±0.63)对(1.91±0.43),P=0.0214)。AMI后6个月,S组左心室舒张末容积指数较NS组小[(69.4±11.7) ml/m2 对(88.5±32.5) ml/m2,P =0.0328],而左室射血分数较高[(67.7±9.2)% 对(59.2±13.3)%,P=0.0394]。NS组在AMI后1个月时的血清非对称性二甲基精氨酸较基线水平显著增多,但S组无变化。(生物谷 Bioon.com)

延伸阅读:

BMJ:他汀类药物未能降低感染风险

SATURN:他汀对冠脉硬化斑块负荷变化之影响的最大规模临床研究公布结果

他汀可否用于心血管事件的一级预防?

IJC:他汀改善冠脉微血管功能障碍

他汀防癌:是耶?非耶?

依折麦布与他汀类药物联合治疗对预防心梗没有优势

强化他汀疗法与糖尿病风险增加有关

他汀不降低家族性高胆固醇血症辅酶Q10浓度

烟酸联合他汀治疗并未降低心血管事件

降压联合他汀——从血压管理到血管管理

热点PK:大剂量他汀序贯治疗使PCI更上一层楼?

Beneficial effects of statin treatment on coronary microvascular dysfunction and left ventricular remodeling in patients with acute myocardial infarction

Kentaro Ishida, Toru Geshi, Akira Nakano, Hiroyasu Uzui, Yasuhiko Mitsuke, Hidehiko Okazawa,Takanori Ueda, Jong-Dae Lee

Transcriptional coregulators control the activity of many transcription factors and are thought to have wide-ranging effects on gene expression patterns. We show here that muscle-specific loss of nuclear receptor corepressor 1 (NCoR1) in mice leads to enhanced exercise endurance due to an increase of both muscle mass and of mitochondrial number and activity. The activation of selected transcription factors that control muscle function, such as MEF2, PPARβ/, and ERRs, underpins these phenotypic alterations. NCoR1 levels are decreased in conditions that require fat oxidation, resetting transcriptional programs to boost oxidative metabolism. Knockdown of gei-8, the sole C. elegans NCoR homolog, also robustly increased muscle mitochondria and respiration, suggesting conservation of NCoR1 function. Collectively, our data suggest that NCoR1 plays an adaptive role in muscle physiology and that interference with NCoR1 action could be used to improve muscle function.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1718691, encodeId=14661e186914d, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Sun Jun 03 07:19:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041802, encodeId=09a22041802a0, content=<a href='/topic/show?id=12e03096104' target=_blank style='color:#2F92EE;'>#冠脉微血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30961, encryptionId=12e03096104, topicName=冠脉微血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 24 22:19:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365280, encodeId=449c136528087, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420962, encodeId=2af91420962fd, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511951, encodeId=ebf615119515d, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1718691, encodeId=14661e186914d, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Sun Jun 03 07:19:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041802, encodeId=09a22041802a0, content=<a href='/topic/show?id=12e03096104' target=_blank style='color:#2F92EE;'>#冠脉微血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30961, encryptionId=12e03096104, topicName=冠脉微血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 24 22:19:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365280, encodeId=449c136528087, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420962, encodeId=2af91420962fd, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511951, encodeId=ebf615119515d, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1718691, encodeId=14661e186914d, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Sun Jun 03 07:19:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041802, encodeId=09a22041802a0, content=<a href='/topic/show?id=12e03096104' target=_blank style='color:#2F92EE;'>#冠脉微血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30961, encryptionId=12e03096104, topicName=冠脉微血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 24 22:19:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365280, encodeId=449c136528087, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420962, encodeId=2af91420962fd, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511951, encodeId=ebf615119515d, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]
    2011-12-14 mgqwxj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1718691, encodeId=14661e186914d, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Sun Jun 03 07:19:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041802, encodeId=09a22041802a0, content=<a href='/topic/show?id=12e03096104' target=_blank style='color:#2F92EE;'>#冠脉微血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30961, encryptionId=12e03096104, topicName=冠脉微血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 24 22:19:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365280, encodeId=449c136528087, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420962, encodeId=2af91420962fd, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511951, encodeId=ebf615119515d, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1718691, encodeId=14661e186914d, content=<a href='/topic/show?id=a93250e8239' target=_blank style='color:#2F92EE;'>#微血管功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50782, encryptionId=a93250e8239, topicName=微血管功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c032593421, createdName=zz81, createdTime=Sun Jun 03 07:19:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041802, encodeId=09a22041802a0, content=<a href='/topic/show?id=12e03096104' target=_blank style='color:#2F92EE;'>#冠脉微血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30961, encryptionId=12e03096104, topicName=冠脉微血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 24 22:19:00 CST 2012, time=2012-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365280, encodeId=449c136528087, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420962, encodeId=2af91420962fd, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511951, encodeId=ebf615119515d, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Wed Dec 14 14:19:00 CST 2011, time=2011-12-14, status=1, ipAttribution=)]

相关资讯

他汀不降低家族性高胆固醇血症辅酶Q10浓度

 《动脉粥样硬化》(Atherosclerosis)杂志2011年6月6日在线发表的一项研究表明,长期、大剂量他汀治疗不能使显性或遗传型家族性高胆固醇血症(FH)患者的血浆辅酶Q10(CoQ10)浓度降低至正常值以下。与未接受他汀治疗的对照组相比,FH患者的动脉僵硬度增加,低CoQ10水平与动脉僵硬度增加相关。   研究者评价了接受他汀治疗的杂合性FH患者,与同等剂量他汀治疗的低密度脂蛋白受体

他汀可否用于心血管事件的一级预防?

  他汀类药物(statin)在20世纪70年代首先由远藤(Endo)等进行研究,自从4S研究开始,一系列大规模的临床试验结果相继证明:他汀类药物可以明显降低心血管事件的发生率和死亡率,在冠心病(CAD)的二级预防中有着重要的作用。   何为一级、二级预防?   一级预防亦称为病因预防,是针对致病因素的预防措施,分针对环境的措施和针对机体的措施。   这一阶段疾病并未发生,但某些危险因素已经

JAMA:强化他汀疗法与糖尿病风险增加有关

强化他汀疗法与糖尿病风险增加有关 作者:美文 来源:美国科学促进会 日期:2011-06-23   据6月22/29日刊《美国医学会杂志》(JAMA)上的一项研究显示,与中等剂量他汀类药物疗法相比,他汀类药物的强化剂量治疗与新发糖尿病风险的增加有关。   与安慰剂相比,他汀类药物治疗在有和没有糖尿病史的人中可显著地降低其心血管疾病的发生率。根据文章的背景资料,最近,对强化剂量与中等剂量他汀疗

SATURN:他汀对冠脉硬化斑块负荷变化之影响的大规模临床研究公布结果

两种强效他汀同样能实现斑块消退 安全性一样良好 2011年11月15日,SATURN研究 (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN)的全部结果在美国心脏协会2011年会上公布。该研究是一项为期104周的随机、双盲、平行分组的多中心IIIb

他汀防癌:是耶?非耶?

 目前他汀类药物已成为全球处方量最多的药物之一,而有关他汀与肿瘤之间关系的争议也从未平息。2011年8月16日,《美国胃肠病学杂志》(Am J Gastroenterol)在线发表一项来自中国台湾的人群为基础的病例对照研究,其结果首次提示,服用他汀类药物可能降低胃癌发生风险,这无疑使人们的目光再次聚焦到这一热点问题。   新证据显示他汀有可能预防胃癌   这项最新研究数据系

氯吡格雷能否“走进”手术室?

           一项荟萃分析对34项研究中22854例因急性冠状动脉综合征(ACS)接受冠状动脉旁路移植术(CABG)治疗的患者进行研究后发现,术前停用氯吡格雷与否,对死亡、CABG术后心肌梗死、卒中和联合主要不良心血管事件发生率无影响。研究5月24日在线发表于《欧洲心脏杂志》(Eur Heart J)。   在CABG术前,氯吡格雷要不要停药,这是一个问题。为此,我们采访了该荟萃分